Nexstim Plc: Composition of the Shareholders’ Nomination Committee
Company Announcement, Helsinki, 24 October 2023 at 3 PM (EEST)
Nexstim Plc: Composition of the Shareholders’ Nomination Committee
Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces the composition of the Shareholders’ Nomination Committee.
Leena Niemistö, Chair of the Board of Nexstim and representative of the Company’s largest shareholder, continues to chair the Nomination Committee. Ossi Haapaniemi, and Kyösti Kakkonen as a representative of Joensuun Kauppa ja Kone Oy continue as members of the committee.
According to the document establishing Nexstim’s Nomination Committee, it must have three to four members. The three largest shareholders of the Company each nominate one member; if a shareholder does not exercise the right to nominate a representative, the right is passed on to the next largest shareholder.
The Nomination Committee will start its work during 2023.
Further information is available on the website www.nexstim.com, or by contacting:
Leena Niemistö, Chair of Board of Directors
+358 9 2727 170
leena.niemisto@nexstim.com
The Company’s Certified Advisor is Erik Penser Bank.
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on Nasdaq First North Growth Market Finland.
For more information, please visit www.nexstim.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Fastsættelse af rentetrigger for rentetilpasningsobligationer1.12.2023 16:35:59 CET | pressemeddelelse
Fastsættelse af rentetrigger for rentetilpasningsobligationer DLR har afsluttet obligationssalget i forbindelse med refinansieringen af rentetilpasningslån med årlig rentetilpasning pr. 2. januar 2024 og har fastsat niveauet for rentetriggeren på de 1-årige rentetilpasningsobligationer i DKK, der kan udløse forlængelse af løbetiden ved næste års refinansiering. Flere oplysninger om rentetriggere kan ses på www.dlr.dk/investor. Oplysninger om obligationssalget i forbindelse med refinansieringerne kan ses samme sted. Spørgsmål vedrørende rentetrigger kan rettes til Fondschef Nikolaj Knudsen på telefon 33 42 07 38. Med venlig hilsen DLR Kredit A/S Vedhæftet fil Fastsættelse af rentetrigger 2023-12-01
Hydro completes sale to Glencore1.12.2023 16:30:00 CET | Press release
Hydro has completed the USD 1.11 billion transaction for the sale of 30 percent interest in the Brazilian alumina refinery Hydro Alunorte and Hydro’s 5 percent interest in the bauxite producer Mineracão Rio do Norte (MRN), together with Vale’s 40 percent stake in MRN. “We are looking forward to work with Glencore to further develop Alunorte. Glencore has broad industrial experience within metals and mining, which adds to the significant progress our bauxite and alumina area has made to bring down the footprint of alumina production. This enables Hydro to strengthen our position in low-carbon aluminium,” says President and CEO, Hilde Merete Aasheim. Hydro and Glencore will continue efforts to reduce carbon emissions from Alunorte through the fuel switch project that aims to substitute fuel oil with LNG, and the electrification of boilers. This will bring Alunorte to the first decile on the global carbon curve already in 2025, positioning Alunorte as a leading supplier of low-carbon alum
Hydro fullfører salget til Glencore1.12.2023 16:30:00 CET | Pressemelding
Hydro har fullført transaksjonen på 1,11 milliarder USD for salg av 30 prosent eierandel i det brasilianske aluminaraffineriet Hydro Alunorte og Hydros eierandel på 5 prosent i bauksittprodusenten Mineracão Rio do Norte (MRN), samt Vales eierandel på 40 prosent i MRN. – Vi ser frem til å samarbeide med Glencore for å videreutvikle Alunorte. Glencore har bred industriell erfaring innen metaller og gruvedrift, noe som forsterker den betydelige fremgangen forretningsområdet vårt for bauksitt og alumina vårt har gjort for å redusere fotavtrykket fra aluminaproduksjonen. Dette gjør Hydro i stand til å styrke vår posisjon innen lavkarbonaluminium, sier konsernsjef Hilde Merete Aasheim. Hydro og Glencore vil fortsette arbeidet med å redusere karbonutslippene fra Alunorte gjennom drivstoffbytteprosjektet som har som mål å erstatte tungolje med LNG, og elektrifisering av fyrkjeler. Dette vil bringe Alunorte til den første desilen på den globale karbonkurven allerede i 2025, og posisjonere Aluno
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS1.12.2023 16:20:00 CET | Press release
Bid procedure, 2023-12-08BondsSWEDEN I/L BOND: 3113. SE0009548704. 2027-12-01 SWEDEN I/L BOND: 3114, SE0013748258, 2030-06-01 Bid date2023-12-08Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered volume (corresponding nominal amount)3113: 300 million SEK +/-300 million SEK 3114: 300 million SEK +/-300 million SEK Highest permitted bid volume (corresponding nominal amount)3113: 300 million SEK per bid 3114: 300 million SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2023-12-12Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK Stockholm, 2023-12-01 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swed
Investeringsselskabet Artha Optimum A/S – Finanskalender for 20241.12.2023 16:12:32 CET | pressemeddelelse
Investeringsselskabet Artha Optimum A/S – Finanskalender for 2024 Selskabsmeddelelse nr. 6, 2023 Hellerup, 1. december 2023 Finanskalender 27. marts 2024: Årsrapport for 2023 24. april 2024: Ordinær generalforsamling 30. august 2024: Halvårsrapport for 1. halvår 2024 Kontakt Spørgsmål vedrørende denne meddelelse kan rettes til: Kristian V. Myrup, direktør +45 70 25 00 05 e-mail: info@artha.dk Med venlig hilsen Investeringsselskabet Artha Optimum A/S Vedhæftet fil Selskabsmeddelelse Optimum 2023 06 finanskalender